Study compares survival for treatments of uncommon eye cancer

(The JAMA Network Journals) In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news